Why the study?
Does elevated Pentraxin-3 (PTX3) predict 3-month mortality in patients with ST-elevation myocardial infarction?
Population
724 patients with acute myocardial infarction (MI) and ST elevation
Comparison
Pentraxin-3 levels assayed at entry and the… vs Other biomarkers including C-reactive protein…
Design
Cohort
Follow-up
3 months
Authors
Loading...
May support PTX3 for post-STEMI risk stratification; leaves open validation before clinical adoption.
Does elevated Pentraxin-3 (PTX3) predict 3-month mortality in patients with ST-elevation myocardial infarction?
In patients with ST-elevation MI, the acute-phase protein PTX3 is a strong independent predictor of 3-month mortality, outperforming CRP and other traditional cardiac biomarkers.
Latini et al. (2004) studied this question.